Tafinlar

Active Ingredient(s): Dabrafenib Mesylate
FDA Approved: * May 29, 2013
Pharm Company: * GLAXOSMITHKLINE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Tafinlar Overview

Dabrafenib (trade name Tafinlar, GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.[1][2] Approvals and indications The Food and Drug...

Read more Tafinlar Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dabrafenib

Recent Tafinlar Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dabrafenib Mesylate
  • Capsule: 50mg, 75mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tafinlar: (4 results)

Sorted by National Drug Code
  • 0078-0681 Tafinlar 75 mg Oral Capsule by Novartis Pharmaceuticals Corporation
  • 0078-0682 Tafinlar 50 mg Oral Capsule by Novartis Pharmaceuticals Corporation
  • 0173-0846 Tafinlar 50 mg Oral Capsule by Glaxosmithkline LLC
  • 0173-0847 Tafinlar 75 mg Oral Capsule by Glaxosmithkline LLC

Other drugs which contain Dabrafenib Mesylate or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 October 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA